Scarica l'app Stockscreener
1.59
2.00%
-0.0324
Dopo l'orario di chiusura:
1.59
Precedente Chiudi:
$1.6224
Aprire:
$1.62
Volume 24 ore:
11,244
Relative Volume:
0.43
Capitalizzazione di mercato:
$8.07M
Reddito:
-
Utile/perdita netta:
$-14.29M
Rapporto P/E:
-0.3985
EPS:
-3.99
Flusso di cassa netto:
$-12.27M
1 W Prestazione:
+5.97%
1M Prestazione:
-27.40%
6M Prestazione:
-61.03%
1 anno Prestazione:
-70.28%
Intervallo 1D:
$1.58
$1.69
Intervallo di 1 settimana:
$1.412
$1.69
Portata 52W:
$1.412
$5.90
Aprea Therapeutics Inc Stock (APRE) Company Profile
Nome
Aprea Therapeutics Inc
Settore
Industria
Telefono
215-948-4119
Indirizzo
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Confronta APRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.59 | 8.07M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-06-22 | Iniziato | H.C. Wainwright | Neutral |
| 2020-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2019-10-28 | Iniziato | JP Morgan | Neutral |
| 2019-10-28 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo
APRE stock touches 52-week low at $1.5 amid market challenges - Investing.com Australia
Adicet Bio Strengthens Board with Ex-Johnson & Johnson VP: Strategic Move for Cell Therapy Pioneer - Stock Titan
Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion - MSN
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
APRE stock touches 52-week low at $1.74 amid market challenges - Investing.com
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock By Investing.com - Investing.com India
Aprea Therapeutics President/CEO Gilad Oren Acquires 5,500 Shares - TradingView
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock - Investing.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
What is Wedbush’s Estimate for APRE FY2025 Earnings? - The AM Reporter
Brokers Issue Forecasts for APRE FY2025 Earnings - Defense World
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN
What is Wedbush’s Estimate for APRE FY2029 Earnings? - Defense World
APRE stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
APRE stock touches 52-week low at $2.15 amid market challenges - Investing.com India
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics Advances Cancer Trials Amid Financial Progress - TipRanks
Aprea Therapeutics repots Q4 EPS (49c) vs. (92c) last year - TipRanks
Aprea Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
APREA THERAPEUTICS Earnings Results: $APRE Reports Quarterly Earnings - Nasdaq
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MyChesCo
Aprea Therapeutics (APRE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MyChesCo
MD Anderson to explore Aprea’s WEE1 kinase inhibitor for HNSCC - BioWorld Online
Aprea Therapeutics partners with MD Anderson for cancer study - Investing.com India
Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc) - Marketscreener.com
Aprea Therapeutics partners with MD Anderson for cancer study By Investing.com - Investing.com South Africa
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - The Manila Times
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MSN
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MSN
Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World
Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Therapeutics Inc Azioni (APRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):